Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229

Watchlist Manager
Zhejiang Ausun Pharmaceutical Co Ltd Logo
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
Watchlist
Price: 8.71 CNY -0.8% Market Closed
Market Cap: 7.2B CNY
Have any thoughts about
Zhejiang Ausun Pharmaceutical Co Ltd?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Zhejiang Ausun Pharmaceutical Co Ltd

Revenue
840.4m CNY
Cost of Revenue
-376.1m CNY
Gross Profit
464.3m CNY
Operating Expenses
-166m CNY
Operating Income
298.4m CNY
Other Expenses
-24.8m CNY
Net Income
273.5m CNY

Margins Comparison
Zhejiang Ausun Pharmaceutical Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
7.2B CNY
55%
36%
33%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
789.8B USD
81%
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
85%
44%
35%
US
Johnson & Johnson
NYSE:JNJ
374.3B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
261B USD
78%
27%
19%
CH
Roche Holding AG
SIX:ROG
209.8B CHF
73%
32%
20%
CH
Novartis AG
SIX:NOVN
181.7B CHF
75%
29%
33%
UK
AstraZeneca PLC
LSE:AZN
153.5B GBP
82%
21%
13%
IE
Endo International PLC
LSE:0Y5F
154.4B USD
68%
11%
-126%
Country CN
Market Cap 7.2B CNY
Gross Margin
55%
Operating Margin
36%
Net Margin
33%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 789.8B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 374.3B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 261B USD
Gross Margin
78%
Operating Margin
27%
Net Margin
19%
Country CH
Market Cap 209.8B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 181.7B CHF
Gross Margin
75%
Operating Margin
29%
Net Margin
33%
Country UK
Market Cap 153.5B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country IE
Market Cap 154.4B USD
Gross Margin
68%
Operating Margin
11%
Net Margin
-126%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Zhejiang Ausun Pharmaceutical Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
7.2B CNY
12%
9%
13%
15%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
789.8B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
374.3B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
261B USD
29%
11%
20%
16%
CH
Roche Holding AG
SIX:ROG
209.8B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
181.7B CHF
35%
16%
20%
15%
UK
AstraZeneca PLC
LSE:AZN
153.5B GBP
17%
6%
14%
12%
IE
Endo International PLC
LSE:0Y5F
154.4B USD
70%
-51%
5%
6%
Country CN
Market Cap 7.2B CNY
ROE
12%
ROA
9%
ROCE
13%
ROIC
15%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 789.8B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.3T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 374.3B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 261B USD
ROE
29%
ROA
11%
ROCE
20%
ROIC
16%
Country CH
Market Cap 209.8B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 181.7B CHF
ROE
35%
ROA
16%
ROCE
20%
ROIC
15%
Country UK
Market Cap 153.5B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country IE
Market Cap 154.4B USD
ROE
70%
ROA
-51%
ROCE
5%
ROIC
6%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top